Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use

This qualitative study examines patient and caregiver experiences with and perceptions of Risk Evaluation and Mitigation Strategy programs with Elements to Assure Safe Use.

[1]  A. Kesselheim,et al.  A Multi-modal Approach to Evaluate the Impact of Risk Evaluation and Mitigation Strategy (REMS) Programs , 2021, Drug Safety.

[2]  A. Kesselheim,et al.  Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program , 2020, Drug Safety.

[3]  J. Ross,et al.  Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing , 2019, JAMA network open.

[4]  P. Lurie,et al.  Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products , 2019, JAMA.

[5]  A. Sarpatwari,et al.  Mitigating Health Risks of Prescription Drugs: Lessons From FDA Oversight of Opioid Products. , 2019, Journal of the American Medical Association (JAMA).

[6]  A. Kesselheim,et al.  The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later. , 2018, The New England journal of medicine.

[7]  Meredith Y. Smith,et al.  What is the quality of drug safety information for patients: An analysis of REMS educational materials , 2018, Pharmacoepidemiology and drug safety.

[8]  J. Zeldis,et al.  Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention , 2017, Drug Safety.

[9]  C. Blanchette,et al.  Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function , 2015, Drugs in context.

[10]  J. Avorn,et al.  Are Risk Evaluation and Mitigation Strategies Associated With Less Off‐Label Use of Medications? The Case of Immune Thrombocytopenia , 2015, Clinical pharmacology and therapeutics.

[11]  Sarah J. Shoemaker,et al.  Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information. , 2014, Patient education and counseling.

[12]  J. Cho,et al.  Reducing Confusion about Grounded Theory and Qualitative Content Analysis: Similarities and Differences , 2014 .

[13]  A. Kesselheim,et al.  Using a drug-safety tool to prevent competition. , 2014, The New England journal of medicine.

[14]  Ingrid M. Nembhard,et al.  Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research , 2009, Circulation.

[15]  Hsiu-Fang Hsieh,et al.  Three Approaches to Qualitative Content Analysis , 2005, Qualitative health research.

[16]  P S Appelbaum,et al.  False hopes and best data: consent to research and the therapeutic misconception. , 1987, The Hastings Center report.